Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

12 Apr 2025

1319.15

9.91%

US tariffs, if extended to Indian pharma industry, will be a challenge: Wockhardt's Huzaifa Khorakiwala

Business Line

Confident that its product, WCK-5222-ZENIC, which has given 97% success in phase-3 clinical trials, would save millions of lives annually

Number of FII/FPI investors increased from 142 to 152 in Dec 2024 qtr.

Wockhardt Ltd.

11 Apr 2025

1319.15

9.91%

Company Update

Wockhardt Ltd - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI ( Depositories and Participants ) Regulations , please find enclosed the Compliance Certificate received from MUFG Intime India Private Limited, Registrar and Transfer Agent of the Company for the quarter ended 31st March, 2025.

pdf

Wockhardt Ltd.

08 Apr 2025

1319.15

9.91%

Company Update

Wockhardt Ltd - 532300 - Intimation For Incorporation Of A Step-Down Subsidiary Company

BSE India

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland) Limited. Consequent to the Incorporation, Wockhardt Antibiotics (Ireland) Limited has become a Step- Down Subsidiary of the Company.

pdf

Wockhardt Ltd.

08 Apr 2025

1319.15

9.91%

Wockhardt Not To Face Significant Impact Of US Tariffs, Says Chairman Khorakiwala

NDTV Profit

Wockhardt's exposure to the US market is just 5%, with plans to exit the generic business soon.

Wockhardt Ltd. is trading below its 30 day SMA of 1330.9

Wockhardt to exit residual US generics business for commercial reasons

Business Line | 07 Apr 2025 1 more

Wockhardt Ltd.

01 Apr 2025

1319.15

9.91%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with ZaynichTM (Zidebactam/Cefepime, WCK 5222)

pdf

Wockhardt Ltd.

27 Mar 2025

1319.15

9.91%

SAST

Wockhardt Ltd - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s ''Code of Conduct for regulating, monitoring, and reporting trading by designated persons'' (''the Code''), the Trading Window for dealing in equity shares of the Company will be closed from 1st April, 2025 until 48 hours after the declaration of audited financial results of the Company for the financial year ended 31st March, 2025.

pdf

Wockhardt Ltd.

18 Feb 2025

1319.15

9.91%

Tariff On Indian Pharma Will Raise Costs For US Buyers, Says Wockhardt's Khorakiwala

NDTV Profit

Indian pharma industry supplies around 40% medicine which American consumers use, the Wockhardt founder chairman said.

Wockhardt Ltd. is trading above its 200 day SMA of 1184.4

Wockhardt Ltd.

14 Feb 2025, 07:14PM

1319.15

9.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

We wish to inform you that the Share allotment Committee of the Board of Directors of the Company has allotted 13,250 equity shares of face value Rs. 5/- each on 14th February, 2025

pdf

Wockhardt Ltd.

14 Feb 2025, 07:13PM

1319.15

9.91%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

We wish to inform you that the Share allotment Committee of the Board of Directors of the Company has allotted 13,250 equity shares of face value Rs. 5/- each on 14th February, 2025

pdf